Article Details

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright

Retrieved on: 2025-03-08 08:33:28

Tags for this article:

Click the tags to see associated articles and topics

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright. View article details on hiswai:

Excerpt

Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company's stock valued at $592,000 after buying an additional 8,058 shares during the ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up